Elagolix
- Generic Name
- Elagolix
- Brand Names
- Oriahnn 28 Day Kit, Orilissa
- Drug Type
- Small Molecule
- Chemical Formula
- C32H30F5N3O5
- CAS Number
- 834153-87-6
- Unique Ingredient Identifier
- 5B2546MB5Z
- Background
Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasin...
- Indication
用于治疗子宫内膜异位症并伴有中度至重度疼痛。
- Associated Conditions
- Heavy Menstrual Bleeding, Moderate to severe pain
- Associated Therapies
- -
A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe Pain
- Conditions
- Interventions
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 11
- Registration Number
- NCT03343067
- Locations
- 🇺🇸
Quad Clinical Research, LLC /ID# 168294, Chicago, Illinois, United States
🇺🇸Seattle Reproductive Medicine /ID# 171079, Seattle, Washington, United States
🇺🇸Central Ohio Clinical Research /ID# 170750, Columbus, Ohio, United States
Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2017-09-05
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 478
- Registration Number
- NCT03271489
- Locations
- 🇺🇸
Exordia Medical Research, Inc /ID# 160853, Fall River, Massachusetts, United States
🇺🇸Health care Affiliates Medical Group /ID# 163324, Santa Ana, California, United States
🇺🇸Duplicate_Northwell Health System - Manhasset /ID# 201058, Manhasset, New York, United States
A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain
- Conditions
- Interventions
- First Posted Date
- 2017-07-11
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 681
- Registration Number
- NCT03213457
- Locations
- 🇺🇸
Clinical Research Adv, Inc. /ID# 149257, Puyallup, Washington, United States
🇺🇸Tidewater Clinical Research /ID# 145397, Virginia Beach, Virginia, United States
🇺🇸Atlanta Women's Research Inst /ID# 145543, Atlanta, Georgia, United States
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
- Conditions
- Interventions
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 433
- Registration Number
- NCT02925494
- Locations
- 🇺🇸
Choice Research, LLC /ID# 153492, Dothan, Alabama, United States
🇺🇸NECCR Fall River LLC /ID# 153274, Fall River, Massachusetts, United States
🇺🇸Mount Vernon Clinical Res, LLC /ID# 153403, Atlanta, Georgia, United States
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 378
- Registration Number
- NCT02691494
- Locations
- 🇺🇸
University of California, Los Angeles /ID# 149760, Los Angeles, California, United States
🇺🇸Mount Vernon Clinical Res, LLC /ID# 144297, Atlanta, Georgia, United States
🇺🇸Clinical Trial Investigators /ID# 152470, Tustin, California, United States
Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
- First Posted Date
- 2016-01-13
- Last Posted Date
- 2020-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 413
- Registration Number
- NCT02654054
- Locations
- 🇺🇸
Houston Ctr for Clin Research /ID# 149149, Sugar Land, Texas, United States
🇺🇸Fellows Research Alliance, Inc /ID# 139655, Savannah, Georgia, United States
🇺🇸University of California, Los Angeles /ID# 144107, Los Angeles, California, United States
Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated Pain
- First Posted Date
- 2014-05-21
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 496
- Registration Number
- NCT02143713
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 815
- Registration Number
- NCT01931670
Safety and Efficacy in Premenopausal Women With Heavy Menstrual Bleeding (HMB) Associated With Uterine Fibroids (UF)
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 571
- Registration Number
- NCT01817530
Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 506
- Registration Number
- NCT01760954
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.